Advances in the treatment of anxiety: Targeting glutamate


Our current psychopharmacological treatments for anxiety disorders evince a number of shortcomings, including troublesome side effects and lack of primary effects. Whereas many new drugs have been developed in the past few decades, most are based on outmoded theories of the pathogenesis of these disorders (i.e., monoamine hypotheses), thus frustrating our… (More)
DOI: 10.1016/j.nurx.2005.12.005


  • Presentations referencing similar topics